Akero Therapeutics Inc

AKRO

NASDAQ. Currency in USD

38.77 -8.18 ( -17.41% )

Real time prices: December 19

Market Cap.

1.81B

Beta (5Y monthly)

-0.88

Price/Earnings

-

EPS (TTM)

-3.36

Forward Dividend

0.00 (0.00%)

Ex-Dividend Date

Volume

4.05M

1y Target Est.

50.33 Day's Range

35.80

41.23

52 Week's Range

7.52

48.38

Historical Summary

Performance

1 Month

-12.23%

YTD

83.33%

1Y

83.59%

2Y

52.12%

23.35% ann.

3Y

104.19%

26.86% ann.

EPS growth

1Y

-19.15%

2Y

-54.84%

32.83% ann.

3Y

10.55%

3.40% ann.

Share Buybacks

3 Months

-9.27%

6 Months

-10.45%

1Y

-10.90%

2Y

-13.71%

3Y

-37.96%

About Akero Therapeutics Inc

Sector

Healthcare

Industry

Biotechnology

Website

https://www.akerotx.com

Exchange

NASDAQ (XNAS)

Shares Outstanding

34.89M

Employees

34 Address

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Latest news

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022....
By Zacks Investment Research - 13 weeks ago

Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers

Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression...
By Zacks Investment Research - 14 weeks ago

AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen...
By Zacks Investment Research - 14 weeks ago

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to...
By Zacks Investment Research - 14 weeks ago

AKRO -17.41%

AVEO 0.07%

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared...
By Zacks Investment Research - 16 weeks ago

AKRO -17.41%

CBAY -3.90%